Head-To-Head Review: JATT Acquisition (NYSE:JATT) vs. Aptose Biosciences (NASDAQ:APTO)

Aptose Biosciences (NASDAQ:APTO) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

26.6% of Aptose Biosciences shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 1.3% of Aptose Biosciences shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aptose Biosciences and JATT Acquisition”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptose Biosciences	N/A	N/A	-$51.21 million	($89.19)	-0.04
JATT Acquisition	N/A	N/A	$6.85 million	N/A	N/A

Profitability

This table compares Aptose Biosciences and JATT Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aptose Biosciences	N/A	-5,683.22%	-300.44%
JATT Acquisition	N/A	-49.58%	2.84%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aptose Biosciences and JATT Acquisition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aptose Biosciences	0	0	3	1	3.25
JATT Acquisition	0	0	0	0	0.00

Aptose Biosciences currently has a consensus target price of $130.00, indicating a potential upside of 3,712.32%. Given Aptose Biosciences’ stronger consensus rating and higher probable upside, research analysts clearly believe Aptose Biosciences is more favorable than JATT Acquisition.

Summary

JATT Acquisition beats Aptose Biosciences on 5 of the 9 factors compared between the two stocks.

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

About JATT Acquisition

JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.